PT  - JOURNAL ARTICLE
AU  - Chaguza, Chrispin
AU  - Hahn, Anne M.
AU  - Petrone, Mary E.
AU  - Zhou, Shuntai
AU  - Ferguson, David
AU  - Breban, Mallery I.
AU  - Pham, Kien
AU  - Peña-Hernández, Mario A.
AU  - Castaldi, Christopher
AU  - Hill, Verity
AU - Yale SARS-CoV-2 Genomic Surveillance Initiative
AU  - Schulz, Wade
AU  - Swanstrom, Ronald I.
AU  - Roberts, Scott C.
AU  - Grubaugh, Nathan D.
TI  - Accelerated SARS-CoV-2 intrahost evolution leading to distinct genotypes during chronic infection
AID  - 10.1101/2022.06.29.22276868
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.06.29.22276868
4099  - http://medrxiv.org/content/early/2022/07/02/2022.06.29.22276868.short
4100  - http://medrxiv.org/content/early/2022/07/02/2022.06.29.22276868.full
AB  - The chronic infection hypothesis for novel SARS-CoV-2 variant emergence is increasingly gaining credence following the appearance of Omicron. Here we investigate intrahost evolution and genetic diversity of lineage B.1.517 during a SARS-CoV-2 chronic infection lasting for 471 days (and still ongoing) with consistently recovered infectious virus and high viral loads. During the infection, we found an accelerated virus evolutionary rate translating to 35 nucleotide substitutions per year, approximately two-fold higher than the global SARS-CoV-2 evolutionary rate. This intrahost evolution led to the emergence and persistence of at least three genetically distinct genotypes suggesting the establishment of spatially structured viral populations continually reseeding different genotypes into the nasopharynx. Finally, using unique molecular indexes for accurate intrahost viral sequencing, we tracked the temporal dynamics of genetic diversity to identify advantageous mutations and highlight hallmark changes for chronic infection. Our findings demonstrate that untreated chronic infections accelerate SARS-CoV-2 evolution, ultimately providing opportunity for the emergence of genetically divergent and potentially highly transmissible variants as seen with Delta and Omicron.Competing Interest StatementNDG is a consultant for Tempus Labs and the National Basketball Association for work related to COVID-19 but is outside the submitted work. UNC is pursuing intellectual property protection for Primer ID sequencing and RS has received nominal royalties from licensing.Funding StatementThis work was supported by the Centers for Disease Control and Prevention (CDC) Broad Agency Announcement #75D30120C09570 (N.D.G.). This work was also supported by NIH award R01-AI140970 to R.S. This research received infrastructure support from the UNC CFAR (P30-AI050410), and the UNC Lineberger Comprehensive Cancer Center (P30-CA016086). We acknowledge the support of the UNC High Throughput Sequencing Facility.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Yale University Human Research Protection Program Institutional Review Board (IRB Protocol ID: 2000031415). Informed consent was obtained from the participant to take part in the study and to have the results of this work published. The coded numbers presented in the tables and figures are not identifiable to the patient.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesA summary of the SARS-CoV-2 samples is available in Table S1. All other data and code are available at https://github.com/grubaughlab/2022_paper_chronic_infection. https://github.com/grubaughlab/2022_paper_chronic_infection